DS8201-A-U205 (Daiichi)

Trial description
A phase 2, open-label, single-arm trial of Trastuzumab Deruxtecan (DS-8201A) in HER2-positive, unresectable ormetastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a Trastuzumab containing regime
Contact name
Dr Lizzie Smyth
Trial start date
Friday, December 13, 2019
Trial end date
Friday, April 1, 2022
Trial tumour type
Show on Radiotherapy